Information for Investigators

Protocol Wording awaiting approval

Landiolol

Landiolol (Rapibloc®, AOP Orphan Pharmaceuticals, Vienna, Austria) is a new ultra-short acting beta blocker that has a half-life of 2.3 to 4 minutes and is about 8 times more selective for the beta 1 receptor than esmolol. Landiolol has been used safely and successfully in septic patients with atrial fibrillation